Effects of CYP3A Induction by Rifampin on the Pharmacokinetics of LY2835219 and Its Metabolites in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Aug 2018
Price : $35 *
At a glance
- Drugs Abemaciclib (Primary) ; Rifampicin
- Indications Breast cancer; Cancer; Mantle-cell lymphoma; Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 20 Apr 2016 Results presented at the 107th Annual Meeting of the American Association for Cancer Research.
- 17 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Nov 2014 Planned End Date changed from 1 Dec 2014 to 1 Nov 2014 according to ClinicalTrials.gov record.